High-throughput and in silico screenings in drug discovery
暂无分享,去创建一个
Sharangdhar S. Phatak | Claudio N Cavasotto | Sharangdhar S Phatak | Clifford C Stephan | C. Cavasotto | C. Stephan
[1] J. Broach,et al. High-throughput screening for drug discovery. , 1996, Nature.
[2] Tudor I. Oprea,et al. Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.
[3] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[4] Bohdan Waszkowycz,et al. Towards improving compound selection in structure-based virtual screening. , 2008, Drug discovery today.
[5] G Wolber,et al. Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. , 2008, Current medicinal chemistry.
[6] Xianyue Ma,et al. Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. , 2005, Journal of medicinal chemistry.
[7] J. An,et al. Structure-based virtual screening of chemical libraries for drug discovery. , 2006, Current opinion in chemical biology.
[8] G. Keserű,et al. Comparative virtual and experimental high-throughput screening for glycogen synthase kinase-3beta inhibitors. , 2005, Journal of medicinal chemistry.
[9] Somesh D. Sharma,et al. Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.
[10] Ajay N. Jain. Effects of protein conformation in docking: improved pose prediction through protein pocket adaptation , 2009, J. Comput. Aided Mol. Des..
[11] Sharangdhar S. Phatak,et al. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction. , 2009, Journal of medicinal chemistry.
[12] S D Pickett,et al. Design of a compound screening collection for use in high throughput screening. , 2004, Combinatorial chemistry & high throughput screening.
[13] D. Vanderwall,et al. Inhibitors of dihydrodipicolinate reductase, a key enzyme of the diaminopimelate pathway of Mycobacterium tuberculosis. , 2001, Biochimica et biophysica acta.
[14] György M Keseru,et al. Hit discovery and hit-to-lead approaches. , 2006, Drug discovery today.
[15] Yun He,et al. Learning from the Data: Mining of Large High-Throughput Screening Databases , 2006, J. Chem. Inf. Model..
[16] Claudio N. Cavasotto,et al. Structure-based development of target-specific compound libraries. , 2006, Drug discovery today.
[17] Maria Paola Costi,et al. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. , 2008, Journal of medicinal chemistry.
[18] Meir Glick,et al. Streamlining lead discovery by aligning in silico and high-throughput screening. , 2006, Current opinion in chemical biology.
[19] Ulrich Rester,et al. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. , 2008, Current opinion in drug discovery & development.
[20] Aurélien Grosdidier,et al. Docking, virtual high throughput screening and in silico fragment-based drug design , 2009, Journal of cellular and molecular medicine.
[21] B. Shoichet,et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.
[22] Chris L Waller,et al. Strategies to support drug discovery through integration of systems and data. , 2007, Drug discovery today.
[23] Claudio N. Cavasotto,et al. Ligand docking and structure-based virtual screening in drug discovery. , 2007, Current topics in medicinal chemistry.
[24] Gianni Chessari,et al. Application of fragment screening by X-ray crystallography to beta-secretase. , 2007, Journal of medicinal chemistry.
[25] Dawoon Jung,et al. Discovery of a novel class of reversible non-peptide caspase inhibitors via a structure-based approach. , 2005, Journal of medicinal chemistry.
[26] Keith T. Butler,et al. Toward accurate relative energy predictions of the bioactive conformation of drugs , 2009, J. Comput. Chem..
[27] Lorenz M Mayr,et al. The Future of High-Throughput Screening , 2008, Journal of biomolecular screening.
[28] Michael K. Gilson,et al. Screening Drug-Like Compounds by Docking to Homology Models: A Systematic Study , 2006, J. Chem. Inf. Model..
[29] Christopher P Austin,et al. High-throughput screening assays for the identification of chemical probes. , 2007, Nature chemical biology.
[30] Claudio N. Cavasotto,et al. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. , 2008, Journal of medicinal chemistry.
[31] Robert Powers,et al. Identification of novel estrogen receptor α antagonists , 2004, The Journal of Steroid Biochemistry and Molecular Biology.
[32] Hongmao Sun,et al. A Universal Molecular Descriptor System for Prediction of LogP, LogS, LogBB, and Absorption , 2004, J. Chem. Inf. Model..
[33] International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome , 2004 .
[34] Ulrich Rester,et al. Dock around the Clock – Current Status of Small Molecule Docking and Scoring , 2006 .
[35] Andy Jennings,et al. Discovery strategies in a pharmaceutical setting: the application of computational techniques , 2006, Expert opinion on drug discovery.
[36] Stephen R. Johnson,et al. Grid computing in large pharmaceutical molecular modeling. , 2008, Drug discovery today.
[37] Lars Karlsson,et al. Identification of a Potent and Selective Noncovalent Cathepsin S Inhibitor , 2004, Journal of Pharmacology and Experimental Therapeutics.
[38] J. Drews. Drug discovery: a historical perspective. , 2000, Science.
[39] Vladimir Makarenkov,et al. Using Clustering Techniques to Improve Hit Selection in High-Throughput Screening , 2006, Journal of biomolecular screening.
[40] Dora M Schnur. Recent trends in library design: 'rational design' revisited. , 2008, Current opinion in drug discovery & development.
[41] Christopher R. Corbeil,et al. Docking Ligands into Flexible and Solvated Macromolecules. 2. Development and Application of Fitted 1.5 to the Virtual Screening of Potential HCV Polymerase Inhibitors , 2008, J. Chem. Inf. Model..
[42] F. Collins,et al. Transforming Environmental Health Protection , 2008, Science.
[43] G. Klebe. Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.
[44] Christopher R. Corbeil,et al. Docking Ligands into Flexible and Solvated Macromolecules. 3. Impact of Input Ligand Conformation, Protein Flexibility, and Water Molecules on the Accuracy of Docking Programs , 2009, J. Chem. Inf. Model..
[45] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .
[46] Robert Powers,et al. Identification of novel estrogen receptor alpha antagonists. , 2004, The Journal of steroid biochemistry and molecular biology.
[47] Anders Karlén,et al. Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. , 2008, Journal of molecular graphics & modelling.
[48] Claudio N. Cavasotto,et al. Homology modeling in drug discovery: current trends and applications. , 2009, Drug discovery today.
[49] J Mestres. Virtual screening: a real screening complement to high-throughput screening. , 2002, Biochemical Society transactions.
[50] A. Persidis. High-throughput screening , 1998, Bio/Technology.
[51] P. Fischer,et al. Computational chemistry approaches to drug discovery in signal transduction , 2008, Biotechnology journal.
[52] Bert Gunter,et al. Improved Statistical Methods for Hit Selection in High-Throughput Screening , 2003, Journal of biomolecular screening.
[53] Sandra Fox,et al. High-Throughput Screening: Update on Practices and Success , 2006, Journal of biomolecular screening.
[54] Hugo O Villar,et al. Computational techniques in fragment based drug discovery. , 2007, Current topics in medicinal chemistry.
[55] C. Harris,et al. How large does a compound screening collection need to be? , 2008, Combinatorial chemistry & high throughput screening.
[56] Gavin Harper,et al. Methods for mining HTS data. , 2006, Drug discovery today.
[57] Claudio N Cavasotto,et al. In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells. , 2006, Bioorganic & medicinal chemistry letters.
[58] Jing Chen,et al. Pocket v.2: Further Developments on Receptor-Based Pharmacophore Modeling , 2006, J. Chem. Inf. Model..
[59] Herbert Köppen. Virtual screening - what does it give us? , 2009, Current opinion in drug discovery & development.
[60] Ricardo Macarron,et al. Critical review of the role of HTS in drug discovery. , 2006, Drug discovery today.
[61] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[62] Magdalena Bacilieri,et al. Ligand-based drug design methodologies in drug discovery process: an overview. , 2006, Current drug discovery technologies.
[63] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[64] Johannes H. Voigt,et al. Cross-Docking of Inhibitors into CDK2 Structures. 1 , 2008, J. Chem. Inf. Model..
[65] Brian K Shoichet,et al. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. , 2006, Journal of medicinal chemistry.
[66] Anirban Mahapatra. Screening for success. , 2008, ACS chemical biology.
[67] F. Guerlesquin,et al. Protein–protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein , 2007, Proceedings of the National Academy of Sciences.
[68] Tudor I. Oprea,et al. Strategies for compound selection. , 2004, Current drug discovery technologies.
[69] Rajarshi Guha,et al. On the interpretation and interpretability of quantitative structure–activity relationship models , 2008, J. Comput. Aided Mol. Des..
[70] Anang A Shelat,et al. Scaffold composition and biological relevance of screening libraries. , 2007, Nature chemical biology.
[71] Jürgen Bajorath,et al. Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.
[72] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[73] P. Hajduk,et al. Predicting protein druggability. , 2005, Drug discovery today.
[74] A. Carnero,et al. High throughput screening in drug discovery , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[75] Bissan Al‐Lazikani,et al. QSAR (Quantitative Structure Activity Relationship) , 2004 .
[76] Haruki Nakamura,et al. A method to enhance the hit ratio by a combination of structure-based drug screening and ligand-based screening , 2008, Advances and applications in bioinformatics and chemistry : AABC.
[77] D. Tweardy,et al. Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation , 2009, PloS one.
[78] W. L. Jorgensen. The Many Roles of Computation in Drug Discovery , 2004, Science.
[79] Stefano Costanzi,et al. Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands , 2009, J. Comput. Aided Mol. Des..
[80] György M. Keserü,et al. The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.
[81] Hongma Sun,et al. Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.
[82] Claudio N. Cavasotto and Narender Singh. Docking and High Throughput Docking: Successes and the Challenge of Protein Flexibility , 2008 .
[83] William Seibel,et al. Theoretical and practical considerations in virtual screening: a beaten field? , 2008, Current medicinal chemistry.
[84] T. Klabunde,et al. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.
[85] Jaroslaw Polanski,et al. Receptor dependent multidimensional QSAR for modeling drug--receptor interactions. , 2009, Current medicinal chemistry.
[86] B. Shoichet,et al. Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.
[87] T. Blundell,et al. Structural biology and drug discovery. , 2005, Drug discovery today.
[88] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[89] Tomas Lundqvist. The devil is still in the details--driving early drug discovery forward with biophysical experimental methods. , 2005, Current opinion in drug discovery & development.
[90] Xianyue Ma,et al. Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of Jak2 tyrosine kinase autophophorylation , 2005 .
[91] Ajay N. Jain,et al. Scoring functions for protein-ligand docking. , 2006, Current protein & peptide science.
[92] J. Bonfield,et al. Finishing the euchromatic sequence of the human genome , 2004, Nature.
[93] Christine Humblet,et al. Lead optimization via high-throughput molecular docking. , 2007, Current opinion in drug discovery & development.
[94] Julian Tirado-Rives,et al. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. , 2006, Journal of medicinal chemistry.
[95] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[96] Johannes H. Voigt,et al. Cross-Docking of Inhibitors into CDK2 Structures. 2 , 2008, J. Chem. Inf. Model..
[97] G. Klebe,et al. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.
[98] David L Mobley,et al. Treating entropy and conformational changes in implicit solvent simulations of small molecules. , 2008, The journal of physical chemistry. B.
[99] Dawoon Jung,et al. Virtual docking approaches to protein kinase B inhibition. , 2005, Journal of medicinal chemistry.
[100] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[101] M. Entzeroth,et al. Emerging trends in high-throughput screening. , 2003, Current opinion in pharmacology.
[102] Gilles Marcou,et al. Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores , 2008, J. Chem. Inf. Model..
[103] Claudio N. Cavasotto,et al. 2,3‐Dihydro‐1‐Benzofuran Derivatives as a Series of Potent Selective Cannabinoid Receptor 2 Agonists: Design, Synthesis, and Binding Mode Prediction through Ligand‐Steered Modeling , 2009, ChemMedChem.
[104] Campbell McInnes,et al. Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.
[105] Jonas Boström,et al. Computational chemistry-driven decision making in lead generation. , 2006, Drug discovery today.
[106] Claudio N. Cavasotto,et al. Protein flexibility in ligand docking and virtual screening to protein kinases. , 2004, Journal of molecular biology.
[107] Martin J Stoermer. Current status of virtual screening as analysed by target class. , 2006, Medicinal chemistry (Shariqah (United Arab Emirates)).
[108] G. Oliva,et al. Virtual screening and its integration with modern drug design technologies. , 2008, Current medicinal chemistry.
[109] Sam Michael,et al. Compound Management for Quantitative High-Throughput Screening , 2008, JALA.
[110] Brian K. Shoichet,et al. Virtual screening of chemical libraries , 2004, Nature.
[111] James Inglese,et al. Reporting data from high-throughput screening of small-molecule libraries. , 2007, Nature chemical biology.
[112] James A. Lumley,et al. Compound selection and filtering in library design , 2005 .
[113] Stephen D. Pickett,et al. Research Papers) Design of a Compound Screening Collection for use in High Throughput Screening , 2004 .
[114] X. Barril,et al. Incorporating protein flexibility into docking and structure-based drug design , 2006, Expert opinion on drug discovery.
[115] M. Drysdale,et al. Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping. , 2007, Bioorganic & medicinal chemistry letters.
[116] Olivier Sperandio,et al. Free resources to assist structure-based virtual ligand screening experiments. , 2007, Current protein & peptide science.
[117] Gisbert Schneider,et al. Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.
[118] Robert Nadon,et al. Statistical practice in high-throughput screening data analysis , 2006, Nature Biotechnology.
[119] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.